Drugs / TQB6411
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07043751 | Jul 2025 → Dec 2027 expected | cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07367529 | Feb 2026 → Dec 2028 expected | lung cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07367516 | Feb → Sep 2026 overdue | esophageal cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗
2025年，中国生物制药（1177.HK）旗下正大天晴、北京泰德制药、礼新医药、南京正大天晴等成员企业共有18款1类创新药首次获得国家药品监督管理局（NMPA）临床试验批准，涵盖肿瘤、代谢、外科/镇痛、呼吸等多个治疗领域，包括ADC（抗体偶联药物）、PROTAC（蛋白降解靶向嵌合体）、双特异性抗体、小分子抑制剂等创新产品。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗ |
| 2025-07-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 完成首例给药！正大天晴EGFR/c-Met双抗ADC（TQB6411）开启Ⅰ期临床 cttq.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB6411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07043751 ↗ |
| Known as | TQB6411 for injection | “TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met.” NCT07043751 ↗ |
| Known as | TQB6411 injection | “Drug: TQB6411 injection” NCT07043751 ↗ |
| Action | Inhibit | “to block the activation of EGFR and c-Met signaling pathways.” NCT07043751 ↗ |
| Modality | Other / unclassified | “antibody-conjugated drug (ADC)” NCT07043751 ↗ |
| Route | Intravenous | “After injecting intravenously” NCT07043751 ↗ |
| Target | EGFR | “TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met.” NCT07043751 ↗ |
| Target | MET | “TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met.” NCT07043751 ↗ |